Treatment of advanced breast cancer: Current status
Treatment of advanced breast cancer: Current status
复制标题
DOI：
10.1097/00001813-199608001-00002
复制
发表时间：
1996-08-01
影响因子：
2.3
通讯作者：
Piccart, M
中科院分区：
文献类型：
--
作者：
Piccart, M
转移性乳腺癌是一个主要的和日益严重的公共卫生问题。这种疾病的5年生存率仅为15%，虽然激素和化疗选择对局部疾病患者的长期生存有显著影响，但对播散性疾病的治疗基本上仍然是姑息性的。迫切需要新的治疗选择来改善转移性乳腺癌患者的前景，特别是那些疾病特征表明预后特别差的患者。多西他赛（Taxotere（R））是一种很有前途的新药，在对蒽环类抗生素耐药的疾病患者和内脏转移患者中显示出令人鼓舞的活性，这两种疾病都表明预后不良。虽然多西他赛目前仅被许可用于蒽环类耐药疾病患者，但这种高活性药物现在应被开发用于一线治疗，并最终用于辅助治疗。
Metastatic breast cancer is a major and increasing public health problem. The 5-year survival for this disease is only 15%, and while hormonal and chemotherapeutic options have had a significant impact on long-term survival for patients with localized disease, treatment for disseminated disease remains essentially palliative. New treatment options are urgently needed to improve the prospects for patients with metastatic breast cancer, particularly for those with disease characteristics indicating a particularly poor prognosis. Docetaxel (Taxotere(R)) is a promising new drug and has shown encouraging activity in patients with disease resistant to anthracyclines and in patients with visceral metastases, both of which indicate a poor prognosis. Although docetaxel is, at present, only licensed for use in patients with anthracycline-resistant disease, this highly active drug should now be developed for first-line treatment, and eventually for adjuvant use.